Compare NCNO & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCNO | ANIP |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2022 | 1999 |
| Metric | NCNO | ANIP |
|---|---|---|
| Price | $17.42 | $79.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $26.07 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 3.4M | 292.5K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 115.15 | ★ 419.23 |
| EPS | 0.05 | ★ 3.32 |
| Revenue | ★ $594,781,000.00 | $206,547,000.00 |
| Revenue This Year | $9.53 | $21.01 |
| Revenue Next Year | $8.97 | $17.59 |
| P/E Ratio | $348.50 | ★ $23.55 |
| Revenue Growth | ★ 10.01 | 2.47 |
| 52 Week Low | $13.80 | $56.71 |
| 52 Week High | $33.92 | $99.50 |
| Indicator | NCNO | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 51.69 | 54.28 |
| Support Level | $13.80 | $78.80 |
| Resistance Level | $18.76 | $83.58 |
| Average True Range (ATR) | 0.76 | 2.26 |
| MACD | -0.08 | -0.12 |
| Stochastic Oscillator | 31.07 | 53.55 |
Ncino Inc is a provider of cloud-based software for financial institutions. It is focused on developing the nCino Platform to transform commercial and small business lending for community and regional banks in the U.S. With the company's platform financial institutions can Operate More Intelligently, Improve Efficiency, Elevate Employee and Client Experiences, and Manage Risk and Compliance Continuously Rather Than Reactively. It has built and acquired technology, including SimpleNexus, DocFox, FullCircl, ILT, Visible Equity, FinSuite, and Sandbox Banking, to augment the nCino Platform's capabilities for mortgage lending, onboarding, account opening, indirect auto lending, and analytics and AI. The company operates as one operating segment.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.